Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

307 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A retrospective analysis of VeriStrat status on outcome of a randomized phase II trial of first-line therapy with gemcitabine, erlotinib, or the combination in elderly patients (age 70 years or older) with stage IIIB/IV non-small-cell lung cancer.
Stinchcombe TE, Roder J, Peterman AH, Grigorieva J, Lee CB, Moore DT, Socinski MA. Stinchcombe TE, et al. Among authors: lee cb. J Thorac Oncol. 2013 Apr;8(4):443-51. doi: 10.1097/JTO.0b013e3182835577. J Thorac Oncol. 2013. PMID: 23370367 Free article. Clinical Trial.
Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small cell lung cancer.
Stinchcombe TE, Morris DE, Lee CB, Moore DT, Hayes DN, Halle JS, Rivera MP, Rosenman JG, Socinski MA. Stinchcombe TE, et al. Among authors: lee cb. J Thorac Oncol. 2008 Mar;3(3):250-7. doi: 10.1097/JTO.0b013e3181653cf4. J Thorac Oncol. 2008. PMID: 18317067 Free article. Clinical Trial.
Long-term follow-up of a phase I/II trial of dose escalating three-dimensional conformal thoracic radiation therapy with induction and concurrent carboplatin and paclitaxel in unresectable stage IIIA/B non-small cell lung cancer.
Stinchcombe TE, Lee CB, Moore DT, Rivera MP, Halle J, Limentani S, Rosenman JG, Socinski MA. Stinchcombe TE, et al. Among authors: lee cb. J Thorac Oncol. 2008 Nov;3(11):1279-85. doi: 10.1097/JTO.0b013e31818b1971. J Thorac Oncol. 2008. PMID: 18978563 Free article. Clinical Trial.
Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically important, and correspond to normal cell types.
Wilkerson MD, Yin X, Hoadley KA, Liu Y, Hayward MC, Cabanski CR, Muldrew K, Miller CR, Randell SH, Socinski MA, Parsons AM, Funkhouser WK, Lee CB, Roberts PJ, Thorne L, Bernard PS, Perou CM, Hayes DN. Wilkerson MD, et al. Among authors: lee cb. Clin Cancer Res. 2010 Oct 1;16(19):4864-75. doi: 10.1158/1078-0432.CCR-10-0199. Epub 2010 Jul 19. Clin Cancer Res. 2010. PMID: 20643781 Free PMC article.
307 results